Histogenics to Explore Strategic Alternatives for NeoCart Cartilage Treatment

Based on FDA feedback for its NeoCart® Phase III clinical trial, which indicated that an additional clinical trial would be required to accept a BLA submission, Histogenics announced that it expects to suspend development of the tissue engineered implant and does not plan to submit a BLA at this time.

While the NeoCart trial resulted in...

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.

Contact Us